0000000000141390

AUTHOR

Laura Mauceri

showing 5 related works from this author

From Neonatal Intensive Care to Neurocritical Care: Is It Still a Mirage? The Sicilian Multicenter Project

2021

Background. Neonatal brain injury (NBI) can lead to a significant neurological disability or even death. After decades of intense efforts to improve neonatal intensive care and survival of critically ill newborns, the focus today is an improved long-term neurological outcome through brain-focused care. The goal of neuroprotection in the neonatal intensive care unit (NICU) is the prevention of new or worsening NBI in premature and term newborns. As a result, the neonatal neurocritical care unit (NNCU) has been emerging as a model of care to decrease NBI and improve the long-term neurodevelopment in critically ill neonates. Purpose. Neurocritical care (NCC) Sicilian project includes three aca…

medicine.medical_specialtyEncountered problemsNeonatal intensive care unitPharmacological therapyArticle SubjectRC86-88.9Critically illbusiness.industryExtremely pretermMEDLINENeurointensive careMedical emergencies. Critical care. Intensive care. First aidCritical Care and Intensive Care Medicineneonatal brain monitoring neurocritical careIntensive caremedicineIntensive care medicinebusinessResearch ArticleCritical Care Research and Practice
researchProduct

Levetiracetam in Neonatal Seizures as First-line Treatment: A Prospective Study

2017

Aim of the Study: The aim of this study is to evaluate the efficacy and safety of levetiracetam (LEV) as first-line treatment of neonatal seizures. Materials and Methods: This study was conducted in patients of Neonatal Intensive Care Unit of Santo Bambino Hospital, University of Catania, Italy, from January to August 2016. A total of 16 neonates with convulsions not associated with major syndromes, which required anticonvulsant therapy, were included and underwent IV LEV at standard doses. Results: All patients responded to treatment, with a variety range of seizure resolution period (from 24 h to 15 days; mean hours: 96 ± 110.95). No patient required a second anticonvulsant therapy. Regar…

Pediatricsmedicine.medical_specialtyEfficiency and safety; levetiracetam; neonatal seizures; prospective studyNeonatal intensive care unitlevetiracetamneonatal seizuresAnticonvulsant therapyNO03 medical and health sciences0302 clinical medicine030225 pediatricsMedicineIn patientProspective cohort studybusiness.industryGeneral NeuroscienceEfficiency and safetyFirst line treatmentEfficiency and safety; levetiracetam; neonatal seizures; prospective study;AnesthesiaPediatrics Perinatology and Child HealthOriginal Articleneonatal seizureLevetiracetambusiness030217 neurology & neurosurgerymedicine.drugprospective study
researchProduct

Ketogenic diet for infants with epilepsy: A literature review.

2020

Abstract The ketogenic diet (KD) is an established, nonpharmacological treatment for drug-resistant epilepsy (DRE). Actually, KD and its variants have been shown to be elective and resolute for patients with glucose transporter type 1 (GLUT1) deficiency. The aim of this review was to study the use of KD and its variants in infancy, including the neonatal age, and demonstrate the safety and efficacy of this treatment in patients with the age of 0–23 months affected by DRE already subjected to pharmacological approach attempts. A literature search was conducted using PubMed as the medical database source. We used the age limit of 0–23 months, and we considered only articles published between …

MalePediatricsmedicine.medical_specialtyDrug Resistant EpilepsyKetogenicmedicine.medical_treatmentDrug-resistant epilepsyDrug-resistant epilepsy Epilepsy Glucose transporter type 1 deficiency Infant Ketogenic diet Diet Ketogenic Disease Management Drug Resistant Epilepsy Epilepsy Female Glucose Transporter Type 1 Humans Infant. Infant Newborn. Male Seizures Treatment OutcomeNeonatal ageNewborn. MaleAge limitlaw.invention03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineRandomized controlled triallawSeizuresmedicineGlucose transporter type 1 deficiencyHumans030212 general & internal medicineProspective cohort studyGlucose Transporter Type 1Epilepsybusiness.industryInfant NewbornDisease ManagementInfantRetrospective cohort studyKetogenic dietInfant. InfantDrug Resistant Epilepsymedicine.diseaseDietTreatment OutcomeNeurologyFemaleNeurology (clinical)businessDiet Ketogenic030217 neurology & neurosurgeryKetogenic dietEpilepsybehavior : EB
researchProduct

Short-Term Neurodevelopmental Outcome in Term Neonates Treated with Phenobarbital versus Levetiracetam: A Single-Center Experience

2019

Background. Phenobarbital (PB) has been traditionally used as the first-line treatment for neonatal seizures. More recently, levetiracetam (LEV) has been increasingly used as a promising newer antiepileptic medication for treatment of seizures in neonates. Objectives. The aim of our study was to compare the effect of PB vs. LEV on short-term neurodevelopmental outcome in infants treated for neonatal seizures. Method. This randomized, one-blind prospective study was conducted on term neonates admitted to the Neonatal Intensive Care Unit of S. Bambino Hospital, University Hospital “Policlinico-Vittorio Emanuele,” Catania, Italy, from February 2016 to February 2018. Thirty term neonates with s…

MalePediatricsmedicine.medical_specialtyNeonatal intensive care unitLevetiracetamArticle Subjectneonatal seizures levetiracetam neurodevelopmental outcomemedicine.medical_treatmentneonatal seizuresNeurological examinationNeurosciences. Biological psychiatry. NeuropsychiatrySingle CenterNO03 medical and health sciences0302 clinical medicineSeizures030225 pediatricsmedicineHumansProspective StudiesProspective cohort studymedicine.diagnostic_testbusiness.industryInfant NewbornAnticonvulsants Treatment Outcome Infant Newborn Italy Levetiracetam Neurodevelopmental Disorders Phenobarbital SeizuresInfantPhenobarbital; neonatal seizures; LevetiracetamGeneral MedicineTerm neonatesNewbornNeuropsychology and Physiological PsychologyAnticonvulsantTreatment OutcomeNeurologyItalyNeurodevelopmental DisordersPhenobarbitalClinical StudyPhenobarbitalFemaleAnticonvulsantsNeurology (clinical)Levetiracetambusiness030217 neurology & neurosurgerymedicine.drugRC321-571Behavioural Neurology
researchProduct

N-BiPAP vs n-CPAP in term neonate with respiratory distress syndrome

2020

Abstract Background Non-invasive respiratory ventilation has greatly improved the evolution of respiratory distress in neonates, especially for preterm infants, but few studies have investigated the use of non-invasive ventilation (NIV) in term infants. It is useful for neonatologists and nurses to identify the optimal ventilation strategy in terms of effectiveness for this group of newborns. The aim of our study was to investigate what type of respiratory support between nasal Continuous Positive Airway Pressure (nCPAP) or nasal Biphasic Positive Airway Pressure (nBiPAP) is more effective in term neonates with RDS. Methods Our study was a retrospective observational study of 78 full term n…

MaleTerm infantsRespiratory distress syndromemedicine.medical_treatmentContinuous positive airway pressureVital signsBiphasic positive airway pressureNOBiphasic Positive Airway PressurePositive-Pressure Respiration03 medical and health sciences0302 clinical medicine030225 pediatricsmedicineHumansBiphasic positive airway pressure; Continuous positive airway pressure; Non-invasive ventilation; Respiratory distress syndrome; Term infants;Continuous positive airway pressureRespiratory systemFull TermRespiratory Distress Syndrome NewbornNoninvasive VentilationRespiratory distressbusiness.industryInfant NewbornObstetrics and Gynecologyrespiratory systemmedicine.diseaseBiphasic positive airway pressure; Continuous positive airway pressure; Non-invasive ventilation; Respiratory distress syndrome; Term infantsTerm infants.PneumothoraxAnesthesiaPediatrics Perinatology and Child HealthNon-invasive ventilationBreathingFemalebusiness030217 neurology & neurosurgeryEarly Human Development
researchProduct